Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

View ORCID ProfileSang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, View ORCID ProfileDae Jung Kim
doi: https://doi.org/10.1101/2020.05.20.20108555
Sang Youl Rhee
1Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sang Youl Rhee
  • For correspondence: bard95@hanmail.net rheesy@khu.ac.kr
Jeongwoo Lee
2Data Science team, Hanmi Pharm. Co., Ltd., Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyewon Nam
2Data Science team, Hanmi Pharm. Co., Ltd., Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dae-Sung Kyoung
2Data Science team, Hanmi Pharm. Co., Ltd., Seoul, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dae Jung Kim
3Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dae Jung Kim
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Dipeptidyl peptidase-4 inhibitor (DPP-4i) and renin–angiotensin system (RAS) blockade are reported to affect the clinical course of coronavirus disease 2019 (COVID-19) in patients with diabetes mellitus (DM). However, the effectiveness of these drugs in large populations is unclear.

Subjects and Methods As of May 2020, data analysis was conducted on all subjects who could confirm their history of claims related to COVID-19 in the National Health Review and Assessment Service database in Korea. Using the COVID-19 and claims data of the past 5 years, we compared the short-term prognosis of COVID-19 infection according to the use of DPP-4i and RAS blockade.

Results Totally, data of 67850 subjects were accessible. Of these, 5080 were confirmed COVID-19. Among these, 832 subjects with DM were selected for analysis in this study. Among the subjects, 263 (31.6%) and 327 (39.3%) were DPP-4i and RAS blockade users, respectively. Thirty-four subjects (4.09%) received intensive care or died. The adjusted odds ratio for severe treatment among DPP-4i users was 0.362 [95% confidence interval (CI), 0.135–0.971], and that for RAS blockade users was 0.599 (95% CI, 0.251–1.431). No synergy was observed for subjects using both drugs.

Conclusion This population-based study suggests that DPP-4i is significantly associated with a better clinical outcome of patients with COVID-19. However, the effect of RAS blockade is not significant.

Competing Interest Statement

Researchers from a pharmaceutical company participated in this study (JL, HN, and D-SK). They are experts on claims data, and their institutions have not intentionally influenced the basic hypothesis of the study, analysis plan, result arrangement, result interpretation, and manuscript preparation. The researchers from other institutions have no conflict of interest to declare.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Institutional Review Board of Kyung Hee University Hospital (no. KHUH 2020-04-067). The requirement for informed consent was waived by the institutional review board because de-identified information was used for the analyses.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Currently, in Korea, medication usage data for the past 5 years for those who have claimed a confirmatory test of COVID-19 are managed as a separate database for research. To protect personal information, the export of raw data is strictly prohibited by law, and research is being performed in a way that provides de-identified results when researchers submit program codes for analysis.

https://hira-covid19.net/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 23, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dae Jung Kim
medRxiv 2020.05.20.20108555; doi: https://doi.org/10.1101/2020.05.20.20108555
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19
Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dae Jung Kim
medRxiv 2020.05.20.20108555; doi: https://doi.org/10.1101/2020.05.20.20108555

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Endocrinology (including Diabetes Mellitus and Metabolic Disease)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (143)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (172)
  • Epidemiology (4904)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (85)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5405)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1831)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)